Although therapeutic options for NSCLC patients with KRAS mutation is lacking, new approaches in the clinical testing such as dual MEK and mTOR inhibition or cytotoxic drugs [31] are being evaluated. Here, MTOR is linked to non-small cell lung carcinoma.